News

Novozymes buys Iogen’s enzymes
Enlarge image

BusinessDenmark

Novozymes buys Iogen’s enzymes

01.02.2013 - With a €50m acquisition Novozymes puts a foot in the pulp & paper, textile, grain-processing and animal feed industries

On January 31st, the Danish enzyme specialist annouced that it will acquire the industrial enzyme business of Canadian cellulosic ethanol specialist Iogen Corporation for €50m. Earn-out payments of up to additional €10m could add to the sum. With the deal Novozymes bags the entire product portfolio of Iogen Bio-Products, including products in development, production sites and IP.

Iogen Bio-Products produces fibre modifying enzymes, such as pulp bleaching enzymes for the pulp and paper branch, fibre processing biocatalysts for textile sector, cellulases and hemicellulases fort he grain-processing and enzymes fort he animal feed industries. Closing of the take-over is expected in February 2013. With the deal Novozymes strenghtens its market position in industrial biotech which complements its already strong position in the cellulosic bioethanol segment that is expanded with aquisitions and collaborations.

© eurobiotechnews.eu/tg 

ResearchUKEU

23.07.2014 In the largest genomic study published on any psychiatric disorder so far, researchers have indentified 83 new locations in the human genome associated with the risk of developing schizophrenia.

BusinessUKIreland

21.07.2014 Abbvie’s tenacious pursuit of British rival Shire is finally paying off: The two companies have unveiled their transatlantic merger worth £32bn (€40bn).

ResearchEUSwitzerland

17.07.2014 A trans-border, cross-disciplinary project that aims to model the human brain in a computer has drawn heavy criticism from scientists pledging to boycott the project.

MergerUK

16.07.2014 After rejecting three merger propositions from US competitor Abbvie, Shire has now given up resistance to the deal and is recommending a new and improved offer worth £31.3bn.

AcquisitionUKDenmarkSpainGermanyFrance

15.07.2014 British specialty pharma company Prostrakan is handing over £230m for Archimedes Pharma Limited, a company that brings its lead product Pecfent and its proprietary drug delivery technology platform into the deal.

FundingEU

11.07.2014 Among the seven newly launched Joint Technology Initiatives (JTI) of Horizon2020 are two with deep roots in biotech: IMI is going into its second round while the newly established Bio-based Industries partnership invests in bioeconomy.

Stock marketNetherlandsUKBelgium

10.07.2014 Not one but two biopharma companies are seeking entry into the stock market: After Abzena raised €25m in an IPO earlier this week, Argen-x has followed suit and sold shares worth €40m.

M and AUKIreland

08.07.2014 Abbvie is determined to bring home British rare disease specialist Shire in a merger worth £30.1bn (€37.9bn). So far, Shire has rejected all offers from the US company.

M and ASwitzerland

04.07.2014 Genentech, a member of Swiss Roche Group, is set to acquire US-biotech Seragon Pharmaceuticals Inc. With the move, Genentech will obtain the rights to investigational breast cancer treatments.

MandAFranceGermany

03.07.2014 Nicox S.A. is stretching beyond the European market: The French eye health specialist is set to acquire Aciex Therapeutics Inc., a US-based pharma company with several ophthalmic therapeutics nearing market maturity.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • THROMBOGENICS (B)9.69 EUR9.24%
  • NOVACYT (F)4.80 EUR9.09%
  • HYBRIGENICS (F)1.85 EUR7.56%

FLOP

  • ANTISOMA (UK)1.32 GBP-14.84%
  • XENETIC BIOSCIENCES (UK)6.00 GBP-14.29%
  • THERAMETRICS (CH)0.08 CHF-11.11%

TOP

  • WILEX (D)3.15 EUR331.5%
  • SANTHERA (CH)68.90 CHF100.3%
  • ADDEX (CH)4.06 CHF84.5%

FLOP

  • MERCK KGAA (D)64.28 EUR-49.5%
  • HYBRIGENICS (F)1.85 EUR-28.3%
  • PROSENSA (NL)9.24 USD-28.0%

TOP

  • SANTHERA (CH)68.90 CHF3507.3%
  • GW PHARMACEUTICALS (UK)422.75 GBP771.6%
  • PAION (D)2.80 EUR305.8%

FLOP

  • CYTOS (CH)0.26 CHF-92.4%
  • EVOCUTIS (UK)0.21 GBP-92.0%
  • PROSENSA (NL)9.24 USD-69.0%

No liability assumed, Date: 24.07.2014